These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16892359)

  • 1. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.
    Rondeau JM; Bitsch F; Bourgier E; Geiser M; Hemmig R; Kroemer M; Lehmann S; Ramage P; Rieffel S; Strauss A; Green JR; Jahnke W
    ChemMedChem; 2006 Feb; 1(2):267-73. PubMed ID: 16892359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
    Räikkönen J; Taskinen M; Dunford JE; Mönkkönen H; Auriola S; Mönkkönen J
    Biochem Biophys Res Commun; 2011 Apr; 407(4):663-7. PubMed ID: 21420384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
    Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
    J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
    Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
    Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure.
    Park J; Lin YS; De Schutter JW; Tsantrizos YS; Berghuis AM
    BMC Struct Biol; 2012 Dec; 12():32. PubMed ID: 23234314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes.
    Mao J; Mukherjee S; Zhang Y; Cao R; Sanders JM; Song Y; Zhang Y; Meints GA; Gao YG; Mukkamala D; Hudock MP; Oldfield E
    J Am Chem Soc; 2006 Nov; 128(45):14485-97. PubMed ID: 17090032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase.
    Ohno K; Mori K; Orita M; Takeuchi M
    Curr Med Chem; 2011; 18(2):220-33. PubMed ID: 21110804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
    Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
    J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
    Leung CY; Park J; De Schutter JW; Sebag M; Berghuis AM; Tsantrizos YS
    J Med Chem; 2013 Oct; 56(20):7939-50. PubMed ID: 23998921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
    Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RG; Oppermann U
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7829-34. PubMed ID: 16684881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
    Sanders JM; Gómez AO; Mao J; Meints GA; Van Brussel EM; Burzynska A; Kafarski P; González-Pacanowska D; Oldfield E
    J Med Chem; 2003 Nov; 46(24):5171-83. PubMed ID: 14613320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay.
    Glickman JF; Schmid A
    Assay Drug Dev Technol; 2007 Apr; 5(2):205-14. PubMed ID: 17477829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
    Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
    J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
    van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
    Biochem Biophys Res Commun; 1999 Oct; 264(1):108-11. PubMed ID: 10527849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation.
    Sanchez VM; Crespo A; Gutkind JS; Turjanski AG
    J Phys Chem B; 2006 Sep; 110(36):18052-7. PubMed ID: 16956297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.